Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xaliproden · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Xaliproden (SR57746A) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Xaliproden (SR57746A) | DRUG | oral administration |
| Placebo | DRUG | oral administration |
| Oxaliplatin | DRUG | IV administration |
| 5-Fluorouracil | DRUG | IV administration |
| Leucovorin | DRUG | IV administration |
Inclusion Criteria: Main inclusion criteria : * Histologically or cytologically-proven metastatic cancer of the colon or rectum. * Metastatic disease not amenable to potentially curative treatment (eg: inoperable metastatic disease). * Male or female aged \>18 years. * WHO Performance Status (PS) ...
Xaliproden is an investigational small molecule studied for Alzheimer disease and for preventing neurotoxicity from oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. It was evaluated in Phase 3 clinical trials for both indications. The drug is not approved and remains in clinical development.
Xaliproden is developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi sponsored the Phase 3 clinical trials of Xaliproden in Alzheimer disease and in metastatic colorectal cancer patients receiving chemotherapy.
Xaliproden has completed Phase 3 clinical trials. It is an investigational drug and has not been approved by regulatory authorities. The completed Phase 3 studies evaluated its efficacy in Alzheimer disease and in preventing chemotherapy-induced neurotoxicity in metastatic colorectal cancer.
Xaliproden has completed three Phase 3 trials. NCT00103649 and NCT00104013 studied the drug in patients with mild-to-moderate Alzheimer disease. NCT00305188 evaluated Xaliproden for preventing neurotoxicity of oxaliplatin/5FU/LV chemotherapy in patients with metastatic colorectal cancer. All trials are completed.
Yes, Xaliproden is also known as SR57746A. Clinical trial records refer to the drug by both names, for example in the Phase 3 studies of Xaliproden (SR57746A) in Alzheimer disease and in chemotherapy-induced neurotoxicity prevention.
Xaliproden is a small molecule designed to provide neuroprotective effects. In clinical trials, it was studied for its potential to slow cognitive decline in Alzheimer disease and to protect nerves from damage caused by oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.